BIOCERES CROP SOLUTIONS CORP BIOX
ASignal's systematic analysis rates BIOX as Bearish.
Reflects the latest available analysis · analyzed Nov 9, 2026
The case on BIOX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Free cash flow positive at $45.61M
- Gross margin at 34.16% indicates some pricing power
- Price near Bollinger Lower Band (0.1849) suggesting potential reversal
- MACD histogram improving (positive momentum shift)
- Severely negative profit margin (-108.54%)
- Negative ROE (-50.07%) indicating poor capital efficiency
- High debt-to-equity ratio (3.69x) signaling financial risk
- Declining revenue growth (YoY: -23.40%)
- Current ratio (0.80x) and quick ratio (0.44x) indicate liquidity concerns
- Low news coverage with only 2 sources
See the full verdict on BIOX
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BIOX
Most investors never get a second opinion, let alone several. ASignal runs BIOX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.